Relevant bibliographies by topics / Iodine radioisotopes; Radioactive; Thyroglobulin

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters

Academic literature on the topic 'Iodine radioisotopes; Radioactive; Thyroglobulin'

Author: Grafiati
Published: 4 June 2021
Last updated: 12 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Iodine radioisotopes; Radioactive; Thyroglobulin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Iodine radioisotopes; Radioactive; Thyroglobulin"

1

ITO, Tomiyasu, Norio NOGAWA, Kunio OOHASHI, Asao NAKAMURA, and Naotake MORIKAWA. "Radioactive iodine absorbing properties of tetrathiafulvalene." RADIOISOTOPES 38, no. 5 (1989): 237–43. http://dx.doi.org/10.3769/radioisotopes.38.5_237.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Matthews, T. J., E. Chua, A. Gargya, J. Clark, K. Gao, and M. Elliott. "Elevated serum thyroglobulin levels at the time of ablative radioactive iodine therapy indicate a worse prognosis in thyroid cancer: an Australian retrospective cohort study." Journal of Laryngology & Otology 130, S4 (July 2016): S50—S53. http://dx.doi.org/10.1017/s0022215116008331.

Full text
Abstract:
AbstractBackground:Serum thyroglobulin is used as a surrogate marker for well-differentiated thyroid carcinoma recurrence. This study investigates whether thyroglobulin measured at the time of ablative radioactive iodine therapy predicts disease-free survival.Methods:A retrospective review was conducted of patients with well-differentiated thyroid carcinoma presenting from 1989 to 2010 at the Royal Prince Alfred Hospital, New South Wales, Australia. Disease-free survival of patients with a significantly elevated stimulated thyroglobulin level (27.5 µg/l or higher) at the time of ablative radioactive iodine therapy was compared to that of patients without a significantly elevated thyroglobulin level using univariate analysis.Results:Patients with a thyroglobulin level of 27.5 µg/l or higher had an increased relative risk of disease recurrence of 4.50 (95 per cent confidence interval = 1.35–15.04). If lateral neck dissection was required at the time of surgery, patients also had an increased relative risk of macroscopic disease recurrence of 4.94 (95 per cent confidence interval = 1.47–16.55).Conclusion:An elevated thyroglobulin level of 27.5 µg/l or higher at the time of ablative radioactive iodine therapy is a prognostic indicator for macroscopic disease recurrence in well-differentiated thyroid carcinoma.
APA, Harvard, Vancouver, ISO, and other styles
3

Gargya, Ash, and Elizabeth Chua. "Focal Bronchiectasis Causing Abnormal Pulmonary Radioiodine Uptake in a Patient with Well-Differentiated Papillary Thyroid Carcinoma." Case Reports in Endocrinology 2012 (2012): 1–3. http://dx.doi.org/10.1155/2012/452758.

Full text
Abstract:
Background. False-positive pulmonary radioactive iodine uptake in the followup of differentiated thyroid carcinoma has been reported in patients with certain respiratory conditions.Patient Findings. We describe a case of well-differentiated papillary thyroid carcinoma treated by total thyroidectomy and radioiodine ablation therapy. Postablation radioiodine whole body scan and subsequent diagnostic radioiodine whole body scans have shown persistent uptake in the left hemithorax despite an undetectable stimulated serum thyroglobulin in the absence of interfering thyroglobulin antibodies. Contrast-enhanced chest computed tomography has confirmed that the abnormal pulmonary radioiodine uptake correlates with focal bronchiectasis.Summary. Bronchiectasis can cause abnormal chest radioactive iodine uptake in the followup of differentiated thyroid carcinoma.Conclusions. Recognition of potential false-positive chest radioactive iodine uptake, simulating pulmonary metastases, is needed to avoid unnecessary exposure to further radiation from repeated therapeutic doses of radioactive iodine.
APA, Harvard, Vancouver, ISO, and other styles
4

Jiang, Yuyan, Jiahui Jin, Jingzheng Fan, Chao Huang, Qiang Jia, Jian Tan, Xianghui He, et al. "Urinary iodine concentration and radioactive iodine therapeutic response in patients with differentiated thyroid cancer." Biomarkers in Medicine 15, no. 11 (August 2021): 879–90. http://dx.doi.org/10.2217/bmm-2020-0745.

Full text
Abstract:
Aim: Urinary iodine concentration (UIC) may assess radioactive iodine ablation. Materials & methods: According the 2015 American Thyroid Association guidelines, patients were categorized into low- to intermediate-risk or high-risk groups. The iodine concentration in the morning urine specimens was measured by the ceric ion-arsenious acid method. Results: In the low- to intermediate-risk group (113 cases), nonexcellent response (non-ER) was associated with higher UIC, higher UIC subgroups (p < 0.05), higher pre-ablative stimulated thyroglobulin levels (p < 0.01). In the high-risk group (68 cases), the non-ER rate was higher in the higher pre-ablative stimulated thyroglobulin group (p < 0.01), but not significantly different between the UIC and UIC subgroups (p > 0.05). Conclusion: The non-ER rate was related to UIC in the low- to intermediate-risk group; however, UIC did not affect the non-ER rate in the high-risk group.
APA, Harvard, Vancouver, ISO, and other styles
5

Wang, Chen, Xin Zhang, Hui Li, Xin Li, and Yansong Lin. "Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis." PLOS ONE 12, no. 7 (July 13, 2017): e0179664. http://dx.doi.org/10.1371/journal.pone.0179664.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

SHIBUYA, Koichi, Kiyonori YAMAOKA, Tomohiro NAGAMATSU, Katsumi HANAMOTO, Shoji KAWASAKI, and Yoshio HIRAKI. "Simple and Easy Method for Measurement of Airborne Radioactive Iodine(125I)." RADIOISOTOPES 51, no. 2 (2002): 66–70. http://dx.doi.org/10.3769/radioisotopes.51.66.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kwong, Norra, Ellen Marqusee, Michael S. Gordon, P. Reed Larsen, Jeffrey R. Garber, Matthew I. Kim, and Erik K. Alexander. "Long-term, treatment-free survival in select patients with distant metastatic papillary thyroid cancer." Endocrine Connections 3, no. 4 (December 2014): 207–14. http://dx.doi.org/10.1530/ec-14-0097.

Full text
Abstract:
Well-differentiated thyroid carcinoma (WDTC) generally has a favorable prognosis. However, patients with distant metastatic disease experience progression of disease with a higher mortality. A subset of patients not previously described may challenge the conventional dogma regarding the progressive nature of all metastatic WDTC. Through analysis of our database, we identified patients with distant metastatic WDTC and persistent, minimally progressive disease. In all patients, persistent metastatic disease was confirmed via tissue biopsy, abnormal PET scan, and/or biochemical elevations in thyroglobulin or antibody levels. Progression of disease was monitored clinically and with repeat imaging. We describe five patients with WDTC and pulmonary metastases, aged 8–43 years at diagnosis. All patients underwent initial surgery and radioactive iodine (RAI) ablation, with some receiving multiple treatments. Persistent pulmonary metastatic disease was confirmed over decades (mean 22 years, range 8–42 years) with minimal progression despite no further treatment beyond thyroid hormone suppression. Persistent disease was biopsy-proven in all patients at a mean of 9.6 years from last RAI treatment. All patients had elevated thyroglobulin or anti-thyroglobulin antibody levels, while three demonstrated metabolically active disease with positive FDG uptake on PET scan, and one patient with persistent radioactive iodine avid pulmonary metastasis 36 years after her last RAI treatment. This case series demonstrates that some patients with distant metastases, even if metabolically active and radioactive iodine resistant, remain stable for decades without further treatment. Clinical awareness of such patients and continual reassessment of disease risk following initial therapy are crucial as aggressive treatment may not be necessary.
APA, Harvard, Vancouver, ISO, and other styles
8

Carhill, Aubrey A., and Rena Vassilopoulou-Sellin. "Durable Effect of Radioactive Iodine in a Patient with Metastatic Follicular Thyroid Carcinoma." Case Reports in Endocrinology 2012 (2012): 1–5. http://dx.doi.org/10.1155/2012/231912.

Full text
Abstract:
Objective. Thyroid cancer is the most common endocrine malignancy and fastest increasing of all cancers in both men and women in the United States. Traditionally, differentiated thyroid cancer (DTC) carries a good prognosis when diagnosed early, but increasingly patients are presenting with late-stage disease and bone metastasis which carries a poor prognosis. Treatment of DTC involves surgical resection followed by radioactive iodine (RAI), which conventionally is thought to reach maximal effectiveness between 6 and 12 months following treatment. We report a case and review the literature surrounding long-term effect of radioactive iodine treatment in metastatic thyroid carcinoma.Methods. Patient clinical encounter and the literature review.Results. We describe a 49-year-old woman with symptomatic metastatic follicular thyroid cancer (FTC) to the spine and radiographic evidence of spinal cord compression who was effectively treated with RAI. Her initial serum thyroglobulin (Tg) levels following total thyroidectomy were 1,343 ng/mL which dramatically dropped to less than 100 ng/mL following RAI. Forty-three months following treatment with RAI, she has experienced complete resolution of her symptoms and continues to maintain persistently low-thyroglobulin levels of less than 100 ng/mL.Conclusions. RAI is believed to reach peak efficacy within 6–12 months; however, little has been reported regarding the long-term duration of benefit. This case demonstrates that the benefits of RAI therapy may be enduring, even in patients with widely metastatic thyroid cancer. It suggests in clinically stable patients with declining thyroglobulin after treatment, that there may not be an immediate need for additional therapy as RAI treatment may provide lasting effects.
APA, Harvard, Vancouver, ISO, and other styles
9

Slonimsky, Einat, and Mark Tulchinsky. "Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of Differentiated Thyroid Cancer." Current Pharmaceutical Design 26, no. 31 (September 17, 2020): 3812–27. http://dx.doi.org/10.2174/1381612826666200605121054.

Full text
Abstract:
: This review of radioactive iodide treatment (RAIT) extends from historical origins to its modern utilization in differentiated thyroid cancer (DTC). The principles embedded in the radiotheragnostics (RTGs) paradigm are detailed. : The diverse approaches in current practice are addressed, and this broad variability represents a major weakness that erodes our specialty’s trust-based relationship with patients and referring physicians. The currently developing inter-specialty collaboration should be hailed as a positive change. It promises to clarify the target-based terminology for RAIT. It defines RAIT of post total thyroidectomy (PTT), presumably benign thyroid as ‘remnant ablation’ (RA). ‘Adjuvant treatment’ (AT) referrers to RAIT of suspected microscopic DTC that is inherently occult on diagnostic imaging. RAIT directed at DTC lesion(s) overtly seen on diagnostic imaging is termed ‘treatment of known disease’ (TKD). : It was recently recognized that a ‘recurrent’ DTC is actually occult residual DTC in the majority of cases. Thyroglobulin with remnant uptake concord (TRUC) method (aka Tulchinsky method) was developed to validate that a benign remnant in the post-thyroidectomy neck bed, as quantified by the RAI uptake, is concordant with a measured thyroglobulin (Tg) level at the time of the initial post-thyroidectomy evaluation. It allows recognition of occult residual DTC contribution to post-thyroidectomy Tg. Case examples demonstrate the application of the TRUC method for a logical selection of a specific RAIT category, using imaging-guided identification and management of RAI-avid versus RAI-nonavid residual DTC, i.e. the radiotheragnostics paradigm.
APA, Harvard, Vancouver, ISO, and other styles
10

Rothenberg, Stephen M., David G. McFadden, Edwin Palmer, Gilbert H. Daniels, and Lori J. Wirth. "Re-differentiation of radioiodine-refractory BRAF V600E-mutant thyroid carcinoma with dabrafenib: A pilot study." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 6025. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.6025.

Full text
Abstract:
6025 Background: Resistance to radioactive iodine is a leading cause of mortality in differentiated thyroid carcinoma. The MAPK pathway is a major determinant of iodine uptake into thyroid carcinoma cells. Mutations in BRAF activate this pathway, resulting in resistance to radioactive iodine. A pilot study using the MEK1/2 inhibitor, selumetinib, (Ho, ASCO 2012) increased radioiodine uptake in a subset of thyroid cancers. Methods: This is a single institution, single arm pilot study investigating the potential for the BRAF inhibitor dabrafenib to induce radioiodine uptake in metastatic, BRAF-mutant, radioiodine-refractory papillary thyroid carcinoma (PTC). The primary endpoint is increased radioiodine uptake demonstrated on a 4mCi 131-I whole body scan. Patients with increased uptake receive 14 additional days of dabrafenib followed by treatment with 150mCi 131-I. Secondary endpoints include safety and tolerability and clinical benefit as measured by decreases in serum thyroglobulin and objective response rate per modified RESIST 1.1. Results: To date, 7 patients have been enrolled. All had negative 131-I scans within 14 months of enrollment. No dose adjustments for toxicity have been needed. One patient developed reversible hypophosphatemia and a second developed a benign skin lesion. 3 of 5 evaluable patients developed radioiodine uptake after 28 days of dabrafenib, and new radioiodine-avid lesions were demonstrated in all three after receiving a therapeutic dose of 131-I. All three patients demonstrated increases in thyroglobulin levels during treatment with dabrafenib. Conclusions: This initial data suggests that a subset of patients with radioiodine-resistant BRAF-mutant PTC demonstrate new iodine uptake following treatment with dabrafenib. Reuptake may correlate with increases in thyroglobulin, suggestive of re-differentiation. It is not yet known whether increased uptake of radioactive iodine will translate into a radiographic response. Two patients failed to convert to radioiodine-sensitive disease; it is possible that BRAF inhibition was incomplete in these patients and/or determinants other than BRAF mutation status contribute to radioiodine sensitivity. Clinical trial information: NCT01534897.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Iodine radioisotopes; Radioactive; Thyroglobulin"

1

Adil-Smith, Iran. "Structural analysis of thyroid hormones by EXAFS and molecular simulation : biological effects of '1'2'5I." Thesis, Brunel University, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.362488.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

GUIMARÃES, Giulliana Nóbrega. "Fatores associados à persistência do carcinoma diferenciado de tireoide um ano após radioiodoterapia." Universidade Federal de Pernambuco, 2015. https://repositorio.ufpe.br/handle/123456789/16677.

Full text
Abstract:
Submitted by Fabio Sobreira Campos da Costa (fabio.sobreira@ufpe.br) on 2016-04-19T11:21:33Z No. of bitstreams: 2 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) DISSERTAÇAO-GIULLIANA_NOBREGA.pdf: 1803238 bytes, checksum: 3e84c45ed9de31b5cd10607f9f195dca (MD5)
Made available in DSpace on 2016-04-19T11:21:33Z (GMT). No. of bitstreams: 2 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) DISSERTAÇAO-GIULLIANA_NOBREGA.pdf: 1803238 bytes, checksum: 3e84c45ed9de31b5cd10607f9f195dca (MD5) Previous issue date: 2015-06-15
CNPq
INTRODUÇÃO: O carcinoma diferenciado de tireoide (CDT) é avaliado e tratado de acordo com fatores prognósticos. Embora tenha um bom prognóstico, 14% dos pacientes considerados como de baixo risco de recorrência podem apresentar doença persistente mesmo com tratamento adequado. Por isso, estudos têm sido realizados no intuito de encontrar outros possíveis preditores de persistência do CDT. OBJETIVO: Avaliar que fatores clínicos, laboratoriais e anatomopatológicos estão associados à persistência do CDT um ano após radioiodoterapia (RIT). METODOLOGIA: Foi realizada uma revisão de prontuários, na qual foram incluídos 375 pacientes portadores de CDT. Foram coletados dos registros os dados clínicos (gênero e idade), resultados de dosagens de hormônio tireoestimulante (TSH), tireoglobulina (Tg) e anticorpo anti-tireoglobulina (AATg) antes e um ano após RIT, resultados de varredura de corpo inteiro (PCI) após dose ablativa de radioiodo (131I) e um ano após tratamento inicial, além de laudos dos exames histopatológicos. A partir dos dados obtidos, foi realizada análise bivariada e as variáveis que apresentaram significância inferior a 20,0% (p < 0,20) foram submetidas à análise multivariada através do modelo de regressão de Poisson. Para se chegar a um valor de Tg estimulada (TgE) capaz de predizer os pacientes que teriam maior chance de persistência de doença, foi realizada uma curva ROC. RESULTADOS: Observou-se associação significativa entre persistência de doença e idade inferior a 45 anos (p=0,001), multifocalidade (p=0.008) e tamanho tumoral entre 2 a 4 cm (p=0,002). Além disso, verificou-se associação significativa entre da TgE e persistência do CDT (p<0,001). O ponto de corte de TgE pré-dose com maior sensibilidade e especificidade para prever persistência de doença foi de 7,4 ng/mL. Utilizando este valor encontramos um valor preditivo negativo (VPN) de 87,5%. CONCLUSÃO: Neste estudo encontramos uma forte associação entre persistência do CDT e faixa etária, tamanho tumoral, multifocalidade e Tg estimulada pré-ablação. A Tg estimulada pré-ablação mostrou-se um valioso preditor de persistência de CDT um ano após RIT. Valores de 7,4 ng/mL ou mais mostraram maior sensibilidade e especificidade para prever este desfecho.
BACKGROUND: Differentiated thyroid carcinoma (CDT) is evaluated and treated according to prognostic factors. Although it has a good prognosis, 14% of the patients which are considered at low risk of recurrence, might have persistent disease despite suitable treatment. Hence, studies have been realized in order to find other possible prognostic predictors for CDT persistence. OBJECTIVE: Assess which clinical, laboratory and pathological factors are associated with persistence of CDT one year after radioiodine therapy (RIT). METHODS: It was performed a chart review, in which was included 375 patients with CDT. Were collected clinical data (age and sex), results of thyroid-stimulating hormone (TSH), thyroglobulin (Tg) and antithyroglobulin antibody (AATg) before and one year after RIT, whole body scan (PCI) results after ablative dose of 131I and one year later and, also histopathological exam reports. From these data, was performed a bivariate analysis and the variables that were significant lower than 20.0% (p <0.20) were submitted to multivariate analysis using Poisson regression model. To achieve a stimulated Tg (TgE) value able to predict which patients would have a greater chance of persistent disease, a ROC curve was performed. RESULTS: A significant association was found between persistence of disease and age less than 45 years (p = 0.001), multifocality (p = 0.008) and tumor size between 2-4 cm (p = 0.002). In addition, there was a significant association between TgE and persistence of CDT (p <0.001). The pre-ablation TgE cutoff with greater sensitivity and specificity in predicting persistence of disease was 7.4 ng / mL. Using this value, we found a negative predictive value (VPN) of 87.5%. CONCLUSION: We found a significant association between persistent CDT and age, tumor size, multifocality and pre-ablation TgE in this study. TgE pre-ablation was shown to be a valuable predictor of persistence CDT one year after RIT. Values of 7.4 ng / ml or more showed greater sensitivity and specificity to predict this outcome.
APA, Harvard, Vancouver, ISO, and other styles
3

Fernandes, Roberta Possato. "Quantificação do RNAm de tireoglobulina em sangue periférico de pacientes com câncer diferenciado de tireóide: acompanhamento a longo prazo." Universidade de São Paulo, 2009. http://www.teses.usp.br/teses/disponiveis/5/5135/tde-15042009-154717/.

Full text
Abstract:
O carcinoma diferenciado de tireóide (CDT) abrange 95% de todas as doenças malignas da tireóide. Nos EUA, aumentou em 2,4 vezes nos últimos anos (1973-2002). O seu tratamento inclui tireoidectomia total, seguido por terapia com radioiodo e supressão do TSH com L-tiroxina. A doença pode recidivar em ~20% dos casos, sendo necessária avaliação periódica através de exames de imagens e dosagem de tireoglobulina sérica (TGs). Os Anticorpos (Acs) anti-TG podem ser detectados em 15 a 25% dos pacientes, comprometendo, parcialmente, o uso da TGs como marcador de recidiva do câncer. Um método alternativo proposto para monitorar os pacientes é a detecção de células tireoidianas em sangue periférico, através da mensuração do RNA mensageiro de TG (RNAm-TG) pela técnica de RTPCR em tempo real. Esta nova metodologia aumenta a sensibilidade da detecção desta molécula. O objetivo deste estudo é verificar a significância da quantificação do RNAm-TG, como método diagnóstico complementar no acompanhamento a longo prazo de pacientes com CDT. Amostras de sangue de 45 pacientes (25 sem metástase, 14 com metástase ganglionar e 6 com metástase à distância) foram coletadas nos tempos: antes e 24, 48, 72 horas, 7 dias, 1, 3, 6, 9 meses, 1, 2, 4, 5, 6 e 7 anos após a dose ablativa de radioiodo. Foi realizada extensiva padronização da técnica com a finalidade de excluir interferências metodológicas, empregando dois genes controles interno (GAPDH e HPRT1) para o cálculo da concentração do RNAm-TG. Concomitantemente foi realizada a mensuração de TGs, perfil hormonal e de anticorpos anti-TG. A pesquisa de corpo inteiro, realizada 7 dias após a dose terapêutica, estabeleceu o estadio clínico inicial dos pacientes. Não foi possível estabelecer um valor de corte para o RNAm-TG. O RNAm-TG não diferenciou os estadios clínicos da doença ao longo do tempo, independente do gene controle interno utilizado, e tampouco quando analisaram-se os dados na presença de Acs anti-TG e TSH30ng/mL. A TGs diferenciou os estadios clínicos ao longo do tempo. Concluiu-se que, o RNAm-TG não é um bom marcador de recidiva do CDT, mesmo quando considerou-se critérios de padronização da técnica, avaliação em longo prazo e presença de Acs anti-TG, sendo assim não poderia ser utilizado como método diagnóstico complementar no acompanhamento de pacientes com CDT. Este estudo demonstra que a técnica de RT-PCR em tempo real é muito sensível perdendo especificidade, inviabilizando sua utilização no acompanhamento dos pacientes com CDT
The differentiated thyroid carcinoma (DTC) encloses 95% of all thyroid malignant disease. In USA, it increased 2,4 times in recent years (1973- 2002). The treatment includes total thyroidectomy, ablation with radioiodine (RAI) followed by TSH suppression with L-Thyroxine. The cancer recurrence occurs in 20% of the cases. Periodic evaluation through imaging examinations and serum thyroglobulin (TG) measurements by imunoassays method is recommended for careful follow-up of these patients. The anti-TG antibodies prevalence is 15-25% and would impair, partially, the serum TG use as a tumor marker. An alternative method to identify the recurrence of the tumor is the thyroid cells detection in peripheral blood, through the TG messenger RNA quantification (mRNA-TG) by real time RT-PCR. This new methodology increases the sensitivity detection for this molecule. The objective of this study was to verify the mRNA-TG peripheral blood quantification significance, as a complementary diagnostic method in the long term follow up of patients with DTC. Fourty five blood samples from patients with DTC have been collected before and 24, 48, 72 hours, 7 days, 1, 3, 6, 9 months, 1, 2, 4, 5, 6 and 7 years after the ablation therapy. Extensive technique standardization for mRNA-TG measurements was carried out to exclude methodological interventions and two housekeeping genes (GAPDH and HPRT1) were used to calculate the mRNA-TG concentrations. Concomitantly, serum TG measurements, hormonal profile and antibodies anti-TG assays were performed. The whole body scan was performed 7 days after RAI ablation to determine the stage of the disease. It was not possible to establish a cut-point value for mRNA-TG. The mRNA-TG did not differentiated the clinical stage of the disease in the long term follow-up and neither in the presence of anti-TG antibodies and TSH30ng/mL. Serum TG was able to differentiate the clinical stage of the patients during the follow-up. In conclusion mRNA-TG is not a good marker for the DCT recurrence, even when technical standardization, long term evaluation and the presence of antibodies anti-TG were considered. Thus it could not be used as a complementary diagnostic method in the DTC patients follow-up. This study confirmed the high sensivity of the real time RT-PCR whereas with very low specificity, consequently is unviable to be used in the DTC patients follow-up
APA, Harvard, Vancouver, ISO, and other styles
4

Harvey, Richard Paul. "Uncertainty of inhalation dose coefficients for representative physical and chemical forms of ¹³¹I." 2002. http://books.google.com/books?id=MldYAAAAMAAJ.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hay, Tristan Ryan. "Medical radionuclides and their impurities in wastewater." Thesis, 2012. http://hdl.handle.net/1957/29342.

Full text
Abstract:
NCRP report No.160 states that medical exposure increased to nearly half of the total radiation exposure of the U.S. population from all sources in 2006 (NCRP 2009). Part of this increase in exposure is due to the rise in nuclear medicine procedures. With this observed growth in medical radionuclide usage, there is an increase in the radionuclide being released into wastewater after the medical procedures. The question then arises: what is the behavior of medical radionuclides and their impurities in the wastewater process? It is important to note that, often, medical radionuclides are not exactly 100% radionuclide pure, but they meet a certain standard of purity. Of particular interest are the longer lived impurities associated with these medical radionuclides. The longer lived impurities have a higher chance of reaching the environment. The goal of this study is to identify the behavior of medical radionuclides and their impurities associated with some of the more common radiopharmaceuticals, including Tc-99m and I-131, and locate and quantify levels of these impurities in municipal wastewater and develop a model that can be used to estimate potential dose and risk to the public.
Graduation date: 2012
Access restricted to the OSU Community at author's request from May 24, 2012 - May 24, 2014
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Iodine radioisotopes; Radioactive; Thyroglobulin"

1

Sheppard, S. C. Importance of chemical speciation of iodine in relation to dose estimates from 129I. Pinawa, Man: Whiteshell Laboratories, Environmental Science Branch, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Styro, B. I. Izotopy ioda i radiat͡s︡ionnai͡a︡ bezopasnostʹ. Sankt-Peterburg: Gidrometeoizdat, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Institute of Medicine (U.S.). Committee on Thyroid Screening Related to I-131 Exposure. and National Research Council (U.S.). Committee on Exposure of the American People to I-131 from the Nevada Atomic Bomb Tests., eds. Exposure of the American people to Iodine-131 from Nevada nuclear-bomb tests: Review of the National Cancer Institute report and public health implications. Washington, D.C: National Academy Press, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

(US), National Research Council. Exposure of the American People to Iodine-131 from Nevada Nuclear-Bomb Tests: Review of the National Cancer Institute Report and Public Health Implications. National Academies Press, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Iodine radioisotopes; Radioactive; Thyroglobulin"

1

Alzahrani, Ali S., Omalkhaire Alshaikh, Sameerah Al-Shehri, and Rafif Farhat. "Radioactive Iodine (I-131) Therapy for Thyroglobulin Positive, Scan Negative Differentiated Thyroid Cancer." In The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego, P1–564—P1–564. Endocrine Society, 2010. http://dx.doi.org/10.1210/endo-meetings.2010.part1.p12.p1-564.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Iodine radioisotopes; Radioactive; Thyroglobulin' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography